Home>Topics>Stocks>Vanda Pharmaceuticals

Vanda Pharmaceuticals VNDA

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Vanda Pharmaceuticals ( VNDA ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 7 Aug 2014

      The following audio is from a conference call that will begin on August 07, 2014 at 10:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    2. Vanda's Hetlioz Launch Progressing as Expected; Stock More Than Fully Valued

      Commentary

      Thu, 7 Aug 2014

      Vanda Pharmaceuticals ' second-quarter results were generally consistent with our expectations, as the firm reported reasonable progress for its U

    3. New Morningstar Analyst Report for Vanda Pharmaceuticals Inc

      Stock Reports

      Thu, 7 Aug 2014

      outstanding, which should help ensure that his interests are well aligned with those of other shareholders. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key

    4. Vanda updates expense guidance after Q2 results

      Headlines

      Thu, 7 Aug 2014

      Vanda Pharmaceuticals ( VNDA -2.8% ) Q2 results : Total Revenues: $10.9M (+31.3%); Operating Expenses: $32.5M (+177.8%); Operating

    5. Vanda seeks award in Fanapt licensing dispute

      Headlines

      Thu, 17 Jul 2014

      In a regulatory filing , Vanda Pharmaceuticals ( VNDA -1.2% ) discloses that it seeks an award of $539M in its arbitration proceeding with Novartis ( NVS -1.1% ) over the licensing

    6. Encouraging Early Signs From Vanda's Hetlioz Launch Outweighed by Higher Cost Structure

      Commentary

      Fri, 9 May 2014

      Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs

    7. Raising Vanda's Fair Value Estimate as Confidence in Tasimelteon's Launch Improves

      Commentary

      Tue, 30 Jul 2013

      We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation

    8. Vanda shares jump as sleep disorder drug moves closer to market

      Headlines

      Tue, 30 Jul 2013

      (Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...

    9. Vanda Cuts Expenses in 1Q as it Prepares for New Drug Application Submission for Tasimelteon

      Commentary

      Thu, 9 May 2013

      Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating

    10. Vanda's Fourth Quarter In Line; Focus Remains on Tasi's Midyear Regulatory Submission

      Commentary

      Tue, 12 Feb 2013

      Vanda VNDA reported fourth-quarter results that matched our expectations, and our attention remains focused on the upcoming catalysts for

    « Prev1234Next »
    Content Partners